ArticleInfection and immunity2009
Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni.
Article in Infection and immunity, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- A systematic review and meta-analysis of Penner serotype prevalence of Campylobacter jejuni in low- and middle-income countries.PloS one · 2021Pooled it
- Pooled it
- Recombinant LAB vector-based multicomponent vaccine against Campylobacter jejuni potentially promoting a healthier microbial balance in the poultry gut.Microbiome · 2026Article
- Comparative Performance and Species-Specific Recovery Biases of Culture-Based Methods forVeterinary sciences · 2026Review
- The Owl Monkey (Aotus spp.) as an Animal Research Model. Part 3: Research Use and Diseases.Journal of medical primatology · 2025Review
- Consortium ofAntibiotics (Basel, Switzerland) · 2024Article
- Campylobacter jejuni virulence factors: update on emerging issues and trends.Journal of biomedical science · 2024Review
- Campylobacter vaccination reduces diarrheal disease and infant growth stunting among rhesus macaques.Nature communications · 2023Article
- Intervention Strategies to ControlMicroorganisms · 2023Review
- Reaction Mechanism and Three-Dimensional Structure of GDP-d-glycero-α-d-manno-heptose 4,6-Dehydratase fromBiochemistry · 2022Article
- Biosynthesis of d-Biochemistry · 2021Article
- Relationships of capsular polysaccharides belonging to Campylobacter jejuni HS1 serotype complex.PloS one · 2021Article
- Vaccines against gastroenteritis, current progress and challenges.Gut microbes · 2020Review
- New and alternative strategies for the prevention, control, and treatment of antibiotic-resistant Campylobacter.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Vaccine-mediated protection againstScience advances · 2020Article
- Article
- Glycoconjugations of Biomolecules by Chemical Methods.Frontiers in chemistry · 2020Review
- An Updated Classification System and Review of the Lipooligosaccharide Biosynthesis Gene Locus inFrontiers in microbiology · 2020Review
- Distribution of genes related to Type 6 secretion system and lipooligosaccharide that induced ganglioside mimicry amongGut pathogens · 2020Article
- Biosynthesis of GDP-d-Biochemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The capsule polysaccharide (CPS) of Campylobacter jejuni is one of the few identified virulence determinants of this important human pathogen. Since CPS conjugate vaccines have been so effective against other mucosal pathogens, we evaluated this approach using CPSs from two strains of C. jejuni, 81-176 (HS23 and HS36 serotype complex) and CG8486 (HS4 serotype complex). The CPSs of 81-176 and CG8486 were independently linked to the carrier protein CRM(197) by reductive amination between an aldehyde(s), strategically created at the nonreducing end of each CPS, and accessible amines of CRM(197). In both cases, the CPS:CRM(197) ratio used was 2:1 by weight. Mass spectrometry and gel electrophoresis showed that on average, each glycoconjugate preparation contained, at least in part, two to five CPSs attached to one CRM(197). When administered subcutaneously to mice, these vaccines elicited robust immune responses and significantly reduced the disease following intranasal challenge with the homologous strains of C. jejuni. The CPS(81-176)-CRM(197) vaccine also provided 100% protection against diarrhea in the New World monkey Aotus nancymaae following orogastric challenge with C. jejuni 81-176.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.